Abbott wins FDA approval for CardioMEMS HF smartphone app updates
Abbott (NYSE:ABT) received regulatory clearance from the U.S. Food and Drug Administration for major software capabilities connected to its implanted heart-monitoring platform.
Todas as matérias desta categoria, das mais recentes às mais antigas.
Abbott (NYSE:ABT) received regulatory clearance from the U.S. Food and Drug Administration for major software capabilities connected to its implanted heart-monitoring platform.
TELUS (NYSE:TU) finalized a key technical milestone alongside AST SpaceMobile by testing direct satellite connectivity with standard mobile devices.
INNOVATE (NYSE:VATE) finalized the divestiture of its majority interest in DBM Global to IES Holdings (NASDAQ:IESC).
Skyworks (NASDAQ:SWKS) finalized its strategic combination with Qorvo, uniting two major players in radio frequency, analog, and power semiconductor solutions.
Clean Harbors (NYSE:CLH) completed the acquisitions of EnviroServe and ES&H for a combined purchase price of $775 million in cash and senior notes.
Earl Davis, BMO Global Asset Management fixed income and money markets head, says it's inevitable that 30-year treasury bond yields will cross 6%. He says it could happen this month and explains the call on "Bloomberg Surveillance."
Nicol Turner Lee, Senior Fellow of Governance Studies at the Brookings Institution joins "Bloomberg Brief" to discuss the impact of data centers on voters as the midterm elections come closer.
DoorDash (NASDAQ:DASH) brand Deliveroo partnered with Coco Robotics to launch autonomous robot deliveries across the UK beginning in Canary Wharf, London, in October.
Establishment Labs Holdings (NASDAQ:ESTA) secured U.S. Food and Drug Administration approval for an expanded range of Motiva SmoothSilk Round and Ergonomix breast implants.
GE HealthCare (NASDAQ:GEHC) executed a definitive agreement to acquire SOFIE Biosciences from Trilantic North America for a cash purchase price of $945 million.
Alector (NASDAQ:ALEC) executed an exclusive global licensing agreement with Genentech for AL050, an investigational enzyme replacement therapy targeting Parkinson’s disease.
Harrow (NASDAQ:HROW) closed the acquisition of TYRVAYA from Viatris to expand its commercial ophthalmic portfolio with an approved dry eye treatment.
Tem um segundo para um cookie? 🍪Os cookies essenciais mantêm a Grafa funcionando bem. Alguns opcionais nos ajudam a ver o que está funcionando para melhorarmos. Você tem o controle — pode mudar de ideia quando quiser. Política de cookies · Política de privacidade